SIRT1 and metabolic dysfunction-associated steatotic liver disease: Among these, Bifidobacteria is the most prevalent in the human gut.[30] Numerous clinical and animal studies have demonstrated that Bifidobacteria’s impact on the SIRT1-mediated signaling pathway contributes to improve nonalcoholic fatty liver disease in rats.[31,32] Furthermore, this specific bifidobacterial strain has shown beneficial effects in reducing complications arising from portal hypertension in cirrhosis.[33] This implies that Actinobacteria may be involved in regulating bile acid secretion, nonalcoholic liver cirrhosis, and portal hypertension.